Targeted markets Poietis operates in medical equipment manufacturing with a focus on 4D bioprinting for tissue engineering and cell therapy. Sales opportunity: approach translational research institutes, university centers, and hospital-based ATMP facilities that require next generation bioprinting platforms and cGMP-compatible workflows.

Strategic partnerships History of partnerships with Scintica and Creatio, plus a cGMP facility installation at UB. Sales angle: collaborate with distributors and contract research organizations to broaden geographic reach and provide integrated solutions including training, validation, and service packages.

Expansion signals Frequent press coverage of events such as TERMIS-EU 2026 and ongoing deployments indicates active market interest in advanced bioprinting. Sales tactic: participate in industry conferences, offer live demonstrations, and build partner ecosystems to accelerate lead generation and deal velocity.

Economic positioning Revenue under 1M with total funding around 8.9M suggests a growth-stage company seeking scale. Sales approach: present ROI-focused proposals, staged deployments, and financing options or leasing to lower adoption barriers for research centers and early adopter clinics.

Technology edge NGB platform enables automation, robotics, sensors and 4D tissue self-organization research. Opportunity: target biotech clusters and hospital R&D centers prioritizing cutting-edge bioprinting capabilities, offering integration services, data analytics, and custom tissue engineering workflows.